PHAXIAM Therapeutics SA (PHXM) Fundamental Analysis & Valuation

NASDAQ:PHXM • US29604W2070

3.1 USD
-0.02 (-0.64%)
At close: Mar 8, 2024
3.1 USD
0 (0%)
After Hours: 3/8/2024, 8:27:22 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This PHXM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, PHXM scores 2 out of 10 in our fundamental rating. PHXM was compared to 520 industry peers in the Biotechnology industry. PHXM has a bad profitability rating. Also its financial health evaluation is rather negative. PHXM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. PHXM Profitability Analysis

1.1 Basic Checks

  • In the past year PHXM has reported negative net income.
  • In the past year PHXM has reported a negative cash flow from operations.
PHXM Yearly Net Income VS EBIT VS OCF VS FCFPHXM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -20M -40M -60M

1.2 Ratios

  • PHXM has a Return On Assets of -0.35%. This is amongst the best in the industry. PHXM outperforms 93.60% of its industry peers.
  • PHXM has a better Return On Equity (-0.62%) than 93.94% of its industry peers.
Industry RankSector Rank
ROA -0.35%
ROE -0.62%
ROIC N/A
ROA(3y)-57.41%
ROA(5y)N/A
ROE(3y)-170.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PHXM Yearly ROA, ROE, ROICPHXM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PHXM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHXM Yearly Profit, Operating, Gross MarginsPHXM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. PHXM Health Analysis

2.1 Basic Checks

  • PHXM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PHXM remains at a similar level compared to 1 year ago.
  • PHXM has a better debt/assets ratio than last year.
PHXM Yearly Shares OutstandingPHXM Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 1M 2M 3M 4M 5M
PHXM Yearly Total Debt VS Total AssetsPHXM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -1.09, we must say that PHXM is in the distress zone and has some risk of bankruptcy.
  • PHXM has a Altman-Z score (-1.09) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.30 indicates that PHXM is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.30, PHXM is doing worse than 71.89% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Altman-Z -1.09
ROIC/WACCN/A
WACC4.88%
PHXM Yearly LT Debt VS Equity VS FCFPHXM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 20M -20M -40M

2.3 Liquidity

  • PHXM has a Current Ratio of 1.78. This is a normal value and indicates that PHXM is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of PHXM (1.78) is worse than 80.13% of its industry peers.
  • A Quick Ratio of 1.78 indicates that PHXM should not have too much problems paying its short term obligations.
  • The Quick ratio of PHXM (1.78) is worse than 78.62% of its industry peers.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.78
PHXM Yearly Current Assets VS Current LiabilitesPHXM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. PHXM Growth Analysis

3.1 Past

  • PHXM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.68%, which is quite impressive.
  • Looking at the last year, PHXM shows a very strong growth in Revenue. The Revenue has grown by 59.04%.
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1025.16%
Revenue 1Y (TTM)59.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-70.86%

3.2 Future

  • The Earnings Per Share is expected to grow by 23.84% on average over the next years. This is a very strong growth
  • The Revenue is expected to decrease by -18.92% on average over the next years. This is quite bad
EPS Next Y77.73%
EPS Next 2Y36.72%
EPS Next 3Y23.84%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%

3.3 Evolution

PHXM Yearly Revenue VS EstimatesPHXM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
PHXM Yearly EPS VS EstimatesPHXM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

1

4. PHXM Valuation Analysis

4.1 Price/Earnings Ratio

  • PHXM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year PHXM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHXM Price Earnings VS Forward Price EarningsPHXM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHXM Per share dataPHXM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • PHXM's earnings are expected to grow with 23.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.72%
EPS Next 3Y23.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHXM Dividend Analysis

5.1 Amount

  • No dividends for PHXM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

PHXM Fundamentals: All Metrics, Ratios and Statistics

PHAXIAM Therapeutics SA

NASDAQ:PHXM (3/8/2024, 8:27:22 PM)

After market: 3.1 0 (0%)

3.1

-0.02 (-0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-20
Inst Owners0.01%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.83M
Revenue(TTM)6.65M
Net Income(TTM)-228.00K
Analysts85
Price Target10.17 (228.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.8%
PT rev (3m)6.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-15.5%
EPS NY rev (3m)-0.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.6
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 2.87
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-4.14
FCFYN/A
OCF(TTM)-4.12
OCFYN/A
SpS1.19
BVpS6.57
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.35%
ROE -0.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.41%
ROA(5y)N/A
ROE(3y)-170.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.21%
Cap/Sales 1.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.78
Altman-Z -1.09
F-Score3
WACC4.88%
ROIC/WACCN/A
Cap/Depr(3y)10.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.01%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1025.16%
EPS Next Y77.73%
EPS Next 2Y36.72%
EPS Next 3Y23.84%
EPS Next 5YN/A
Revenue 1Y (TTM)59.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-70.86%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%
EBIT growth 1Y51.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.84%
EBIT Next 3Y11.18%
EBIT Next 5YN/A
FCF growth 1Y44.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.05%
OCF growth 3YN/A
OCF growth 5YN/A

PHAXIAM Therapeutics SA / PHXM FAQ

What is the fundamental rating for PHXM stock?

ChartMill assigns a fundamental rating of 2 / 10 to PHXM.


Can you provide the valuation status for PHAXIAM Therapeutics SA?

ChartMill assigns a valuation rating of 1 / 10 to PHAXIAM Therapeutics SA (PHXM). This can be considered as Overvalued.


What is the profitability of PHXM stock?

PHAXIAM Therapeutics SA (PHXM) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for PHXM stock?

The Earnings per Share (EPS) of PHAXIAM Therapeutics SA (PHXM) is expected to grow by 77.73% in the next year.